WEBVTT LABMICE.>> IF YOU ARE OBESE AND YOU GETPROSTATE CANCER, YOU ARE MORELIKELY TO DIE OF PROTSTATECANCER AND HAVE A MOREAGGRESSIVE FORM.WE'VE KNOWN THAT.RHONDELLA: DR. GLENN BUBLEYSHOWS US THE DIFFERENCE INPROSTATES THAT LOSE ONE OR TWOGENES. TWO IS A BIG DEAL >> THIS IS WHAT NO MUTATION,-- THIS IS WHAT ONE GENEMUTATION LOOKS LIKE.THEN LOOK WHAT HAPPENS WHEN YOUADD THE LOSS OF THIS GENE.RHONDELLA: BUBLEY'S BOSS AT BETHISRAEL DEACONESS CANCER CENTERDID THE RESEARCH, AND LEARNEDLOSS OF PML CAN BE A DEATHSENTENCE, BUT DOESN'T HAPPENVERY FREQUENTLY.HOWEVER, FAT MIMICS THAT GENELOSS.DR. PIER PANDOLFI'S PAPERSUGGESTS CREATION OF AN OBSESITY-- AN OBESITY DRUG COULD TREATPROSTATE PATIENTS. >> BECAUSE HE IDENTIFIED ACOMPOUND OR MOLECULE TO MAKECANCER LESS AGGRESSIVE INANIMAL MODELS, IN A PERFECTWORLD, IT WOULD BE OBESE MENWITH A LOT OF FAT ISSUES WOULD-- THAT WE COULD USE THEMOLECULE AND SEE IF WE COULD GETTHEIR CANCER TO BE LESSAGGRESSIVE, EVEN REGRESS AND GETSMALLER.RHONDELLA: A HIGH FAT DIETCAUSES THE CANCER TO GROWRAPIDLY.LOSING WEIGHT, AN OBVIOUS GOALFOR PATIENTS. BUT SHORT OF THAT,A FAT BLOCKING DRUG COULD SAVELIVES.>> IF WE CAN HIT THIS PATHWAYWITH FATOSTATIN, WE MAYBE ABLETO DO THE SAME THING AS WEIGHTLOSS.RHONDELLA: IT IS UNCLEAR IF WHATIS BEING CALLED FATOSTATIN WOULDWORK IN MEN LIKE IT DOES IN LABMICE.PHARMACEUTICALS WILL HOPE LEESTART WORKING ON IT SOON.